We are live on ! Find out more
SAGE icon

Sage Therapeutics

Delisted

SAGE was delisted on the 30th of July, 2025.

176 hedge funds and large institutions have $278M invested in Sage Therapeutics in 2024 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 51 increasing their positions, 58 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more call options, than puts

Call options by funds: $2.74M | Put options by funds: $1.1M

1% more funds holding

Funds holding: 175 → 176 (+1)

0.5% less ownership

Funds ownership: 84.2% → 83.7% (-0.5%)

6% less capital inflows, than outflows

Capital inflows: $71.3M | Capital outflows: $76M

12% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 58

21% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 24

Holders
176
Holders Change
+1
Holders Change %
+0.57%
% of All Funds
2.31%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
19
Increased
51
Reduced
58
Closed
24
Calls
$2.74​M
Puts
$1.1​M
Net Calls
+$1.64​M
Net Calls Change
-⁠$754​K

SAGE Hedge Fund Activity: Q4 2024 in Review

176 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2024, worth a combined $278M — down 26% from $374M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of SAGE and 19 opened new positions — a net loss of 5 holders — while 58 trimmed existing stakes and 51 added.

The largest buyer was Morgan Stanley, adding an estimated $23.1M. The largest seller was RTW Investments, cutting an estimated $15.8M.

  • 176 institutional investors held Sage Therapeutics (SAGE) as of Q4 2024, up from 175 in Q3 2024.
  • Funds reported $278M of Sage Therapeutics stock for Q4 2024, down 26% quarter-over-quarter.
  • 19 funds opened new Sage Therapeutics positions in Q4 2024 and 24 closed out, a net change of -5 holders.
  • The largest Sage Therapeutics buyer in Q4 2024 was Morgan Stanley, an estimated $23.1M added.
  • The largest Sage Therapeutics seller in Q4 2024 was RTW Investments, an estimated $15.8M sold.

Based on aggregated 13F filings for Q4 2024.